As previously reported, BofA analyst Tazeen Ahmad upgraded BioNTech (BNTX) to Buy from Neutral with an unchanged price target of $239, citing the view that its oncology pipeline could be the "next driver of value" and seeing a positive read-through from the recent update from rival Moderna (MRNA) and Merck’s (MRK) PCV program in melanoma. The oncology pipeline – including iNeST, FixVac, CAR-T and others – represents the "next loge of growth for the company" and Ahmad sees potential for upside as these programs mature, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BNTX:
- BioNTech upgraded to Buy from Neutral at BofA
- Canada approves Pfizer, BioNTech booster vaccine for children 5 to 12
- Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
- Pfizer, BioNTech get FDA FTD for mRNA-based combination vaccine candidate
- Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years